A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
17 02 2021
Historique:
received: 28 10 2019
accepted: 19 11 2020
entrez: 18 2 2021
pubmed: 19 2 2021
medline: 2 3 2021
Statut: epublish

Résumé

Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10

Identifiants

pubmed: 33597508
doi: 10.1038/s41467-020-20496-3
pii: 10.1038/s41467-020-20496-3
pmc: PMC7890067
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1078

Subventions

Organisme : NCI NIH HHS
ID : U01 CA176726
Pays : United States
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P50 CA116201
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA050385
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164917
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA199277
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA179715
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128931
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA156733
Pays : United States
Organisme : Cancer Research UK
ID : C1275/A19187
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA176785
Pays : United States
Organisme : CIHR
ID : CRN-87521
Pays : Canada
Organisme : NCI NIH HHS
ID : RC4 CA153828
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA142996
Pays : United States
Organisme : Cancer Research UK
ID : C1287/A10710
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P50 CA125183
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA164920
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA168524
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA161032
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A8385
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA097396
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA176726
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : Cancer Research UK
ID : C1275/C22524
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1287/A16563
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA058860
Pays : United States
Organisme : Cancer Research UK
ID : C12292/A11174
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U10 CA027469
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A10692
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K07 CA092044
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000124
Pays : United States
Organisme : Cancer Research UK
ID : 11174
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C490/A16561
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA100374
Pays : United States
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C490/A10124
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA116167
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A8384
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214545
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128978
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148537
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA116167
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177150
Pays : United States
Organisme : Cancer Research UK
ID : C1275/A11699
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037517
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130423
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R25 CA112486
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A15007
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : N02CP65504
Pays : United States
Organisme : Department of Health
ID : IS-BRC-1215-20007
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA077398
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA054281
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132839
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : CIHR
ID : GPH-129344
Pays : Canada
Organisme : NCI NIH HHS
ID : U01 CA058860
Pays : United States
Organisme : Cancer Research UK
ID : 10118
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA098758
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 ES044005
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148065
Pays : United States
Organisme : Cancer Research UK
ID : C1275/A15956
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1281/A12014
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1287/A11990
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8197/A16565
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z01 ES049033
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA192393
Pays : United States
Organisme : Cancer Research UK
ID : C1287/A10118
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA054281
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA140286
Pays : United States
Organisme : NCI NIH HHS
ID : N02CP11019
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES009089
Pays : United States

Investigateurs

Ophélie Bertrand (O)
Sandrine Caputo (S)
Anaïs Dupré (A)
Marine Le Mentec (M)
Muriel Belotti (M)
Anne-Marie Birot (AM)
Bruno Buecher (B)
Emmanuelle Fourme (E)
Marion Gauthier-Villars (M)
Lisa Golmard (L)
Claude Houdayer (C)
Virginie Moncoutier (V)
Antoine de Pauw (A)
Claire Saule (C)
Olga Sinilnikova (O)
Sylvie Mazoyer (S)
Francesca Damiola (F)
Laure Barjhoux (L)
Carole Verny-Pierre (C)
Mélanie Léone (M)
Nadia Boutry-Kryza (N)
Alain Calender (A)
Sophie Giraud (S)
Olivier Caron (O)
Marine Guillaud-Bataille (M)
Brigitte Bressac-de-Paillerets (B)
Yves- Jean Bignon (YJ)
Nancy Uhrhammer (N)
Christine Lasset (C)
Valérie Bonadona (V)
Pascaline Berthet (P)
Dominique Vaur (D)
Laurent Castera (L)
Tetsuro Noguchi (T)
Cornel Popovici (C)
Hagay Sobol (H)
Violaine Bourdon (V)
Tetsuro Noguchi (T)
Audrey Remenieras (A)
Catherine Noguès (C)
Isabelle Coupier (I)
Pascal Pujol (P)
Aurélie Dumont (A)
Françoise Révillion (F)
Claude Adenis (C)
Danièle Muller (D)
Emmanuelle Barouk-Simonet (E)
Françoise Bonnet (F)
Virginie Bubien (V)
Nicolas Sevenet (N)
Michel Longy (M)
Christine Toulas (C)
Rosine Guimbaud (R)
Laurence Gladieff (L)
Viviane Feillel (V)
Dominique Leroux (D)
Hélène Dreyfus (H)
Christine Rebischung (C)
Magalie Peysselon (M)
Fanny Coron (F)
Laurence Faivre (L)
Amandine Baurand (A)
Caroline Jacquot (C)
Geoffrey Bertolone (G)
Sarab Lizard (S)
Fabienne Prieur (F)
Marine Lebrun (M)
Caroline Kientz (C)
Sandra Fert Ferrer (SF)
Véronique Mari (V)
Laurence Vénat-Bouvet (L)
Capucine Delnatte (C)
Stéphane Bézieau (S)
Isabelle Mortemousque (I)
Florence Coulet (F)
Chrystelle Colas (C)
Florent Soubrier (F)
Mathilde Warcoin (M)
Johanna Sokolowska (J)
Myriam Bronner (M)
Marie-Agnès Collonge-Rame (MA)
Alexandre Damette (A)
Paul Gesta (P)
Hakima Lallaoui (H)
Jean Chiesa (J)
Denise Molina-Gomes (D)
Olivier Ingster (O)
Helen Gregory (H)
Zosia Miedzybrodzka (Z)
Patrick J Morrison (PJ)
Kai-Ren Ong (KR)
Alan Donaldson (A)
Mark T Rogers (MT)
M John Kennedy (MJ)
Mary E Porteous (ME)
Carole Brewer (C)
Rosemarie Davidson (R)
Louise Izatt (L)
Angela Brady (A)
Julian Barwell (J)
Julian Adlard (J)
Claire Foo (C)
Fiona Lalloo (F)
Lucy E Side (LE)
Jacqueline Eason (J)
Alex Henderson (A)
Lisa Walker (L)
Rosalind A Eeles (RA)
Jackie Cook (J)
Katie Snape (K)
Diana Eccles (D)
Alex Murray (A)
Emma McCann (E)
Stephen Fox (S)
Ian Campbell (I)
Amanda Spurdle (A)
Penny Webb (P)
Anna de Fazio (A)
Margaret Tassell (M)
Judy Kirk (J)
Geoff Lindeman (G)
Melanie Price (M)
Melissa Southey (M)
Roger Milne (R)
Sid Deb (S)
David Bowtell (D)
Annemieke H van der Hout (AH)
Ans M W van den Ouweland (AMW)
Arjen R Mensenkamp (AR)
Carolien H M van Deurzen (CHM)
Carolien M Kets (CM)
Caroline Seynaeve (C)
Christi J van Asperen (CJ)
Cora M Aalfs (CM)
Encarna B Gómez Garcia (EB)
Flora E van Leeuwen (FE)
G H de Bock (GH)
Hanne E J Meijers-Heijboer (HEJ)
Inge M Obdeijn (IM)
J Margriet Collée (JM)
J J P Gille (JJP)
Jan C Oosterwijk (JC)
Juul T Wijnen (JT)
Lizet E van der Kolk (LE)
Maartje J Hooning (MJ)
Margreet G E M Ausems (MGEM)
Marian J E Mourits (MJE)
Marinus J Blok (MJ)
Matti A Rookus (MA)
Muriel A Adank (MA)
Rob B van der Luijt (RB)
T C T E F van Cronenburg (TCTEF)
Carmen C van der Pol (CC)
Nicola S Russell (NS)
Sabine Siesling (S)
Lucy Overbeek (L)
R Wijnands (R)
Judith L de Lange (JL)
Christine Clarke (C)
Dinny Graham (D)
Mythily Sachchithananthan (M)
Deborah Marsh (D)
Rodney Scott (R)
Robert Baxter (R)
Desmond Yip (D)
Jane Carpenter (J)
Alison Davis (A)
Nirmala Pathmanathan (N)
Peter Simpson (P)

Commentaires et corrections

Type : ErratumIn

Références

Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
pubmed: 25220842 doi: 10.1002/ijc.29210
Pharoah, P. D. P., Day, N. E., Duffy, S., Easton, D. F. & Ponder, B. A. J. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int. J. Cancer 71, 800–809 (1997).
pubmed: 9180149 doi: 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B
Nelson, H. D. et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 160, 255–266 (2014).
pubmed: 24366442 doi: 10.7326/M13-1684
Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
pubmed: 28632866 doi: 10.1001/jama.2017.7112
Antoniou, A. C. et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 18, 4442–4456 (2009).
pubmed: 19656774 pmcid: 2782243 doi: 10.1093/hmg/ddp372
Antoniou, A. C. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population. Nat. Genet. 42, 885–892 (2010).
pubmed: 20852631 pmcid: 3130795 doi: 10.1038/ng.669
Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353–361 (2013).
pubmed: 23535729 pmcid: 3771688 doi: 10.1038/ng.2563
Thomas, G. et al. A multi-stage genome-wide association in breast cancer identifies two novel risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41, 579–584 (2009).
pubmed: 19330030 pmcid: 2928646 doi: 10.1038/ng.353
Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015).
pubmed: 26414678 pmcid: 4626285 doi: 10.1038/ng.3404
Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nat. Genet. 45, 392–398e2 (2013).
pubmed: 23535733 pmcid: 3771695 doi: 10.1038/ng.2561
Couch, F. J. et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat. Commun. 7, 11375 (2016).
Lin, W.-Y. et al. Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum. Mol. Genet 24, 285–298 (2015).
pubmed: 25168388 doi: 10.1093/hmg/ddu431
Milne, R. L. et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum. Mol. Genet. 23, 6096–6111 (2014).
pubmed: 24943594 pmcid: 4204770 doi: 10.1093/hmg/ddu311
Haiman, C. A. et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nat. Genet. 43, 1210–1214 (2011).
pubmed: 22037553 pmcid: 3279120 doi: 10.1038/ng.985
Bojesen, S. E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45, 371–384.e2 (2013).
pubmed: 23535731 pmcid: 3670748 doi: 10.1038/ng.2566
Ghoussaini, M. et al. Evidence that the 5p12 variant rs10941679 confers susceptibility to estrogen-receptor-positive breast cancer through FGF10 and MRPS30 regulation. Am. J. Hum. Genet. 99, 903–911 (2016).
pubmed: 27640304 pmcid: 5065698 doi: 10.1016/j.ajhg.2016.07.017
Glubb, D. M. et al. Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am. J. Hum. Genet. 96, 5–20 (2015).
pubmed: 25529635 pmcid: 4289692 doi: 10.1016/j.ajhg.2014.11.009
Gaudet, M. M. et al. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genet. 9, e1003173 (2013).
Siddiq, A. et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum. Mol. Genet. 21, 5373–5384 (2012).
pubmed: 22976474 pmcid: 3510753 doi: 10.1093/hmg/dds381
Dunning, A. M. et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat. Genet. 48, 374–386 (2016).
pubmed: 26928228 pmcid: 4938803 doi: 10.1038/ng.3521
Sawyer, E. et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 10, e1004285 (2014).
pubmed: 24743323 pmcid: 3990493 doi: 10.1371/journal.pgen.1004285
Easton, D. F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
pubmed: 17529967 pmcid: 2714974 doi: 10.1038/nature05887
Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 42, 504–507 (2010).
pubmed: 20453838 pmcid: 3632836 doi: 10.1038/ng.586
Orr, N. et al. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Hum. Mol. Genet. 24, 2966–2984 (2015).
pubmed: 25652398 pmcid: 4406292 doi: 10.1093/hmg/ddv035
Darabi, H. et al. Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression. Am. J. Hum. Genet. 97, 22–34 (2015).
pubmed: 26073781 pmcid: 4572510 doi: 10.1016/j.ajhg.2015.05.002
Meyer, K. B. et al. Fine-scale mapping of the fgfr2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am. J. Hum. Genet. 93, 1046–1060 (2013).
pubmed: 24290378 pmcid: 3852923 doi: 10.1016/j.ajhg.2013.10.026
French, J. D. et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am. J. Hum. Genet. 92, 489–503 (2013).
pubmed: 23540573 pmcid: 3617380 doi: 10.1016/j.ajhg.2013.01.002
Zeng, C. et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 18, 64 (2016).
Ghoussaini, M. et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat. Genet. 44, 312–318 (2012).
pubmed: 22267197 pmcid: 3653403 doi: 10.1038/ng.1049
Udler, M. S. et al. Fine scale mapping of the breast cancer 16q12 locus. Hum. Mol. Genet 19, 2507–2515 (2010).
pubmed: 20332101 pmcid: 2876886 doi: 10.1093/hmg/ddq122
Darabi, H. et al. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Sci. Rep. 6, 32512 (2016).
pubmed: 27600471 pmcid: 5013272 doi: 10.1038/srep32512
Long, J. et al. Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer. PLOS Genet 8, e1002532 (2012).
pubmed: 22383897 pmcid: 3285588 doi: 10.1371/journal.pgen.1002532
Cai, Q. et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat. Genet. 46, 886–890 (2014).
pubmed: 25038754 pmcid: 4127632 doi: 10.1038/ng.3041
Long, J. et al. A Common Deletion in the APOBEC3 Genes and Breast Cancer Risk. J. Natl Cancer Inst. 105, 573–579 (2013).
pubmed: 23411593 pmcid: 3627644 doi: 10.1093/jnci/djt018
Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92–94 (2017).
pubmed: 29059683 pmcid: 5798588 doi: 10.1038/nature24284
Mavaddat, N. et al. Prediction of breast cancer risk based on profiling with common genetic variants. J. Natl. Cancer Inst. 107, djv036 (2015).
Pashayan, N., Morris, S., Gilbert, F. J. & Pharoah, P. D. P. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.1901 (2018).
Mavaddat, N. et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am. J. Hum. Genet. 104, 21–34 (2019).
pubmed: 30554720 doi: 10.1016/j.ajhg.2018.11.002
Antoniou, A. C. et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet. 81, 1186–1200 (2007).
pubmed: 17999359 pmcid: 2276351 doi: 10.1086/522611
Garcia-Closas, M. et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 4, e1000054 (2008).
pubmed: 18437204 pmcid: 2291027 doi: 10.1371/journal.pgen.1000054
Antoniou, A. C. et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet. 82, 937–948 (2008).
pubmed: 18355772 pmcid: 2427217 doi: 10.1016/j.ajhg.2008.02.008
Silva, L. D. & Lakhani, S. R. Pathology of hereditary breast cancer. Mod. Pathol. 23, S46–S51 (2010).
pubmed: 20436502 doi: 10.1038/modpathol.2010.37
Antoniou, A. C. et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 20, 3304–3321 (2011).
pubmed: 21593217 pmcid: 3652640 doi: 10.1093/hmg/ddr226
Antoniou, A. C. et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 14, R33 (2012).
pubmed: 22348646 pmcid: 3496151 doi: 10.1186/bcr3121
Couch, F. J. et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 9, e1003212 (2013).
Kuchenbaecker, K. B. et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 16, 3416 (2014).
Lawrenson, K. et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nat. Commun. 7, 12675 (2016).
Milne, R. L. et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat. Genet. 49, 1767–1778 (2017).
pubmed: 29058716 pmcid: 5808456 doi: 10.1038/ng.3785
Kuchenbaecker, K. B. et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 109, djw302 (2017).
Chenevix-Trench, G. et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 9, 104 (2007).
pubmed: 17466083 pmcid: 1868919 doi: 10.1186/bcr1670
Pierce, B. L. & Ahsan, H. Case-only genome-wide interaction study of disease risk, prognosis and treatment. Genet. Epidemiol. 34, 7–15 (2010).
pubmed: 19434715 pmcid: 2861332
Ottman, R. Gene–environment interaction: definitions and study designs. Prev. Med. 25, 764–770 (1996).
pubmed: 8936580 pmcid: 2823480 doi: 10.1006/pmed.1996.0117
Andrieu, N. & Goldstein, A. M. Epidemiologic and genetic approaches in the study of gene-environment interaction: an overview of available methods. Epidemiol. Rev. 20, 137–147 (1998).
pubmed: 9919434 doi: 10.1093/oxfordjournals.epirev.a017976
Fachal, L. et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature genetics, 52, 56–73 (2020).
pubmed: 31911677 pmcid: 6974400 doi: 10.1038/s41588-019-0537-1
Whittemore, A. S. Assessing environmental modifiers of disease risk associated with rare mutations. Hum. Hered. 63, 134–143 (2007).
pubmed: 17283442 doi: 10.1159/000099185
CIMBA - Consortium of Investigators of Modifiers of BRCA1/2 —. http://cimba.ccge.medschl.cam.ac.uk/ (2017).
Turner, A. et al. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS ONE 8, e56817 (2013).
pubmed: 23457619 pmcid: 3574069 doi: 10.1371/journal.pone.0056817
Zheng, T., Wang, A., Hu, D. & Wang, Y. Molecular mechanisms of breast cancer metastasis by gene expression profile analysis. Mol. Med. Rep. 16, 4671–4677 (2017).
pubmed: 28791367 pmcid: 5647040 doi: 10.3892/mmr.2017.7157
Sharma, D. K., Bressler, K., Patel, H., Balasingam, N. & Thakor, N. Role of Eukaryotic initiation factors during cellular stress and cancer progression. J. Nucleic Acids 2016, 8235121 (2016).
HANNA, S. et al. StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion. Int. J. Oncol. 44, 1499–1511 (2014).
pubmed: 24627003 pmcid: 4027929 doi: 10.3892/ijo.2014.2330
Piegorsch, W. W., Weinberg, C. R. & Taylor, J. A. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat. Med. 13, 153–162 (1994).
pubmed: 8122051 doi: 10.1002/sim.4780130206
Kulminski, A. M. Complex phenotypes and phenomenon of genome-wide inter-chromosomal linkage disequilibrium in the human genome. Exp. Gerontol. 46, 979–986 (2011).
pubmed: 21907271 doi: 10.1016/j.exger.2011.08.010
Escala-Garcia, M. et al. Genome-wide association study of germline variants and breast cancer-specific mortality. Br. J. Cancer 120, 647–657 (2019).
pubmed: 30787463 pmcid: 6461853 doi: 10.1038/s41416-019-0393-x
BCAC - The Breast Cancer Association Consortium —. http://bcac.ccge.medschl.cam.ac.uk/ (2017).
Amos, C. I. et al. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 26, 126–135 (2017).
doi: 10.1158/1055-9965.EPI-16-0106
Consortium, T. 1000 G. P. A global reference for human genetic variation. Nature 526, 68–74 (2015).
doi: 10.1038/nature15393
Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179–181 (2011).
pubmed: 22138821 doi: 10.1038/nmeth.1785
O’Connell, J. et al. A General approach for haplotype phasing across the full spectrum of relatedness. PLOS Genet. 10, e1004234 (2014).
pubmed: 24743097 pmcid: 3990520 doi: 10.1371/journal.pgen.1004234
Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
Browning, B. L. & Browning, S. R. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84, 210–223 (2009).
pubmed: 19200528 pmcid: 2668004 doi: 10.1016/j.ajhg.2009.01.005
Hohenlohe, P. A., Bassham, S., Currey, M. & Cresko, W. A. Extensive linkage disequilibrium and parallel adaptive divergence across threespine stickleback genomes. Philos. Trans. R. Soc. B Biol. Sci. 367, 395–408 (2012).
doi: 10.1098/rstb.2011.0245
Umbach, D. M. & Weinberg, C. R. Designing and analysing case-control studies to exploit independence of genotype and exposure. Stat. Med. 16, 1731–1743 (1997).
pubmed: 9265696 doi: 10.1002/(SICI)1097-0258(19970815)16:15<1731::AID-SIM595>3.0.CO;2-S
Spurdle, A. B. et al. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 16, 3419 (2014).
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 490, 61–70 (2012).
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
pubmed: 21527027 pmcid: 3218867 doi: 10.1186/gb-2011-12-4-r41
GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).
doi: 10.1038/ng.2653
Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633–641 (2013).
pubmed: 23374354 pmcid: 4165609 doi: 10.1016/j.cell.2012.12.034
Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinforma. Oxf. Engl. 28, 1353–1358 (2012).
doi: 10.1093/bioinformatics/bts163
Fullwood, M. J. et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462, 58–64 (2009).
pubmed: 19890323 pmcid: 2774924 doi: 10.1038/nature08497
Corradin, O. et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 24, 1–13 (2014).
pubmed: 24196873 pmcid: 3875850 doi: 10.1101/gr.164079.113
He, B., Chen, C., Teng, L. & Tan, K. Global view of enhancer–promoter interactome in human cells. Proc. Natl Acad. Sci. USA 111, E2191–E2199 (2014).
pubmed: 24821768 pmcid: 4040567 doi: 10.1073/pnas.1320308111
Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455–461 (2014).
pubmed: 24670763 pmcid: 5215096 doi: 10.1038/nature12787
Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).
pubmed: 24119843 doi: 10.1016/j.cell.2013.09.053
Dixon, J. R. et al. Integrative detection and analysis of structural variation in cancer genomes. Nat. Genet. 50, 1388–1398 (2018).
pubmed: 30202056 pmcid: 6301019 doi: 10.1038/s41588-018-0195-8
McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795 pmcid: 4893825 doi: 10.1186/s13059-016-0974-4

Auteurs

Juliette Coignard (J)

Genetic Epidemiology of Cancer team, Inserm, U900, Paris, France.
Institut Curie Paris, Paris, France.
Mines ParisTech Fontainebleau, Paris, France.
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
PSL University Paris, Paris, France.
Paris Sud University, Orsay, France.

Michael Lush (M)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Jonathan Beesley (J)

Department of Genetics and Computational Biology QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Tracy A O'Mara (TA)

Department of Genetics and Computational Biology QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Joe Dennis (J)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Jonathan P Tyrer (JP)

Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Daniel R Barnes (DR)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Lesley McGuffog (L)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Goska Leslie (G)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Manjeet K Bolla (MK)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Muriel A Adank (MA)

Family Cancer Clinic, The Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.

Simona Agata (S)

Immunology and Molecular Oncology, Unit Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Thomas Ahearn (T)

Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.

Kristiina Aittomäki (K)

Department of Clinical Genetics, Helsinki University Hospital University of Helsinki, Helsinki, Finland.

Irene L Andrulis (IL)

Fred A. Litwin Center for Cancer Genetics Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Department of Molecular Genetics University of Toronto, Toronto, ON, Canada.

Hoda Anton-Culver (H)

Department of Epidemiology, Genetic Epidemiology Research Institute University of California Irvine, Irvine, CA, USA.

Volker Arndt (V)

Division of Clinical Epidemiology and Aging Research German Cancer Research Center (DKFZ), Heidelberg, Germany.

Norbert Arnold (N)

Department of Gynaecology and Obstetrics University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
Institute of Clinical Molecular Biology University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.

Kristan J Aronson (KJ)

Department of Public Health Sciences, and Cancer Research Institute Queen's University, Kingston, ON, Canada.

Banu K Arun (BK)

Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Annelie Augustinsson (A)

Department of Cancer Epidemiology, Clinical Sciences Lund University, Lund, 22242, Sweden.

Jacopo Azzollini (J)

Unit of Medical Genetics, Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Daniel Barrowdale (D)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Caroline Baynes (C)

Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Heiko Becher (H)

Institute for Medical Biometrics and Epidemiology University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Marina Bermisheva (M)

Institute of Biochemistry and Genetics Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.

Leslie Bernstein (L)

Department of Population Sciences Beckman Research Institute of City of Hope, Duarte, CA, USA.

Katarzyna Białkowska (K)

Department of Genetics and Pathology Pomeranian Medical University Szczecin, Szczecin, Poland.

Carl Blomqvist (C)

Department of Oncology, Helsinki University Hospital University of Helsinki, Helsinki, Finland.
Department of Oncology Örebro University Hospital, Örebro, Sweden.

Stig E Bojesen (SE)

Copenhagen General Population Study, Herlev and Gentofte Hospital Copenhagen University Hospital, Herlev, Denmark.
Department of Clinical Biochemistry, Herlev and Gentofte Hospital Copenhagen University Hospital, Herlev, Denmark.
Faculty of Health and Medical Sciences University of Copenhagen, Copenhagen, Denmark.

Bernardo Bonanni (B)

Division of Cancer Prevention and Genetics IEO, European Institute of Oncology IRCCS, Milan, Italy.

Ake Borg (A)

Department of Oncology Lund University and Skåne University Hospital, Lund, Sweden.

Hiltrud Brauch (H)

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
iFIT-Cluster of Excellence University of Tübingen, Tübingen, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Barbara Burwinkel (B)

Molecular Epidemiology Group, C080 German Cancer Research Center (DKFZ), Heidelberg, Germany.
Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg University of Heidelberg, Heidelberg, Germany.

Saundra S Buys (SS)

Department of Medicine Huntsman Cancer Institute, Salt Lake City, UT, USA.

Trinidad Caldés (T)

Molecular Oncology Laboratory CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.

Maria A Caligo (MA)

SOD Genetica Molecolare University Hospital, Pisa, Italy.

Daniele Campa (D)

Department of Biology University of Pisa, Pisa, Italy.
Division of Cancer Epidemiology German Cancer Research Center (DKFZ), Heidelberg, Germany.

Brian D Carter (BD)

Behavioral and Epidemiology Research Group American Cancer Society Atlanta, Atlanta, GA, USA.

Jose E Castelao (JE)

Oncology and Genetics Unit Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH) University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Stephen J Chanock (SJ)

Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.

Wendy K Chung (WK)

Departments of Pediatrics and Medicine, Columbia University, New York, NY, USA.

Kathleen B M Claes (KBM)

Centre for Medical Genetics Ghent University, Gent, Belgium.

Christine L Clarke (CL)

Westmead Institute for Medical Research University of Sydney, Sydney, NSW, Australia.

J Margriet Collée (JM)

Department of Clinical Genetics Erasmus University Medical Center, Rotterdam, The Netherlands.

Don M Conroy (DM)

Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Kamila Czene (K)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Mary B Daly (MB)

Department of Clinical Genetics Fox Chase Cancer Center Philadelphia, Philadelphia, PA, USA.

Peter Devilee (P)

Department of Pathology Leiden University Medical Center, Leiden, The Netherlands.
Department of Human Genetics Leiden University Medical Center, Leiden, The Netherlands.

Orland Diez (O)

Oncogenetics Group Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Clinical and Molecular Genetics Area University Hospital Vall d'Hebron, Barcelona, Spain.

Yuan Chun Ding (YC)

Department of Population Sciences Beckman Research Institute of City of Hope, Duarte, CA, USA.

Susan M Domchek (SM)

Basser Center for BRCA, Abramson Cancer Center University of Pennsylvania, Philadelphia, PA, USA.

Thilo Dörk (T)

Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.

Isabel Dos-Santos-Silva (I)

Department of Non-Communicable Disease Epidemiology London School of Hygiene and Tropical Medicine, London, UK.

Alison M Dunning (AM)

Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Miriam Dwek (M)

School of Life Sciences University of Westminster, London, UK.

Diana M Eccles (DM)

Faculty of Medicine University of Southampton, Southampton, UK.

A Heather Eliassen (AH)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Epidemiology Harvard TH Chan School of Public Health, Boston, MA, USA.

Christoph Engel (C)

Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany.

Mikael Eriksson (M)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

D Gareth Evans (DG)

Genomic Medicine, Division of Evolution and Genomic Sciences The University of Manchester, Manchester Academic Health Science Centre, Manchester Universities Foundation Trust, St Mary's Hospital, Manchester, UK.
Genomic Medicine, North West Genomics hub Manchester Academic Health Science Centre, Manchester Universities Foundation Trust, St Mary's Hospital, Manchester, UK.

Peter A Fasching (PA)

David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology University of California at Los Angeles, Los Angeles, CA, USA.
Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN University Hospital Erlangen, Friedrich-Alexander-University, Erlangen-Nuremberg, Erlangen, Germany.

Henrik Flyger (H)

Department of Breast Surgery, Herlev and Gentofte Hospital Copenhagen University Hospital, Herlev, Denmark.

Florentia Fostira (F)

Molecular Diagnostics Laboratory, INRASTES National Centre for Scientific Research íDemokritosí, Athens, Greece.

Eitan Friedman (E)

The Susanne Levy Gertner Oncogenetics Unit Chaim Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine Tel Aviv University, Ramat Aviv, Israel.

Lin Fritschi (L)

School of Public Health Curtin University, Perth, Western Australia, Australia.

Debra Frost (D)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Manuela Gago-Dominguez (M)

Genomic Medicine Group, Galician Foundation of Genomic Medicine Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
Moores Cancer Center University of California, San Diego La Jolla, CA, USA.

Susan M Gapstur (SM)

Behavioral and Epidemiology Research Group American Cancer Society Atlanta, Atlanta, GA, USA.

Judy Garber (J)

Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.

Vanesa Garcia-Barberan (V)

Medical Oncology Department, Hospital Clínico San Carlos Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Montserrat García-Closas (M)

Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.

José A García-Sáenz (JA)

Medical Oncology Department, Hospital Clínico San Carlos Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Mia M Gaudet (MM)

Behavioral and Epidemiology Research Group American Cancer Society Atlanta, Atlanta, GA, USA.

Simon A Gayther (SA)

Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Andrea Gehrig (A)

Department of Human Genetics University Würzburg, Würzburg, Germany.

Vassilios Georgoulias (V)

Department of Medical Oncology University Hospital of Heraklion, Heraklion, Greece.

Graham G Giles (GG)

Cancer Epidemiology Division Cancer Council Victoria, Melbourne, VIC, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health Monash University, Clayton, VIC, Australia.

Andrew K Godwin (AK)

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

Mark S Goldberg (MS)

Department of Medicine, McGill University, Montréal, QC, Canada.
Division of Clinical Epidemiology, Royal Victoria Hospital McGill University Montréal, Montréal, QC, Canada.

David E Goldgar (DE)

Huntsman Cancer Institute and Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA.

Anna González-Neira (A)

Human Cancer Genetics Programme Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Mark H Greene (MH)

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics National Cancer Institute, Bethesda, MD, USA.

Pascal Guénel (P)

Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP) INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, France.

Lothar Haeberle (L)

Department of Gynaecology and Obstetrics, University Hospital Erlangen Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.

Eric Hahnen (E)

Center for Hereditary Breast and Ovarian Cancer Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Center for Integrated Oncology (CIO) Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Christopher A Haiman (CA)

Department of Preventive Medicine, Keck School of Medicine University of Southern California, Los Angeles, CA, USA.

Niclas Håkansson (N)

Department of Oncology, Södersjukhuset, Stockholm, Sweden.

Per Hall (P)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Oncology, Södersjukhuset, Stockholm, Sweden.

Ute Hamann (U)

Molecular Genetics of Breast Cancer German Cancer Research Center (DKFZ), Heidelberg, Germany.

Patricia A Harrington (PA)

Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Steven N Hart (SN)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Wei He (W)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Frans B L Hogervorst (FBL)

Family Cancer Clinic, The Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.

Antoinette Hollestelle (A)

Department of Medical Oncology, Family Cancer Clinic Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

John L Hopper (JL)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.

Darling J Horcasitas (DJ)

New Mexico Oncology Hematology Consultants, University of New Mexico, Albuquerque, NM, USA.

Peter J Hulick (PJ)

Center for Medical Genetics NorthShore University HealthSystem, Evanston, IL, USA.
The University of Chicago Pritzker School of Medicine Chicago, Chicago, IL, USA.

David J Hunter (DJ)

Department of Epidemiology Harvard TH Chan School of Public Health, Boston, MA, USA.
Program in Genetic Epidemiology and Statistical Genetics Harvard TH Chan School of Public Health Boston, Boston, MA, USA.
Nuffield Department of Population Health University of Oxford, Oxford, UK.

Evgeny N Imyanitov (EN)

NN Petrov Institute of Oncology, St. Petersburg, Russia.

Agnes Jager (A)

Department of Medical Oncology, Family Cancer Clinic Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Anna Jakubowska (A)

Department of Genetics and Pathology Pomeranian Medical University Szczecin, Szczecin, Poland.
Independent Laboratory of Molecular Biology and Genetic Diagnostics Pomeranian Medical University, Szczecin, Poland.

Paul A James (PA)

Sir Peter MacCallum Department of Oncology The University of Melbourne, Melbourne, VIC, Australia.
Parkville Familial Cancer Centre Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

Uffe Birk Jensen (UB)

Department of Clinical Genetics Aarhus, University Hospital, Aarhus, Denmark.

Esther M John (EM)

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.

Michael E Jones (ME)

Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.

Rudolf Kaaks (R)

Division of Cancer Epidemiology German Cancer Research Center (DKFZ), Heidelberg, Germany.

Pooja Middha Kapoor (PM)

Division of Cancer Epidemiology German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Genetics and Epidemiology The Institute of Cancer Research, London, UK.

Beth Y Karlan (BY)

Faculty of Medicine University of Heidelberg, Heidelberg, Germany.
David Geffen School of Medicine, Department of Obstetrics and Gynecology University of California at Los Angeles, Los Angeles, CA, USA.

Renske Keeman (R)

Womenís Cancer Program at the Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Elza Khusnutdinova (E)

Institute of Biochemistry and Genetics Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.
Division of Molecular Pathology The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Johanna I Kiiski (JI)

Department of Genetics and Fundamental Medicine Bashkir State Medical University, Ufa, Russia.

Yon-Dschun Ko (YD)

Department of Obstetrics and Gynecology, Helsinki University Hospital University of Helsinki, Helsinki, Finland.

Veli-Matti Kosma (VM)

Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH Johanniter Krankenhaus, Bonn, Germany.
Translational Cancer Research Area University of Eastern Finland, Kuopio, Finland.
Institute of Clinical Medicine, Pathology and Forensic Medicine University of Eastern Finland, Kuopio, Finland.

Peter Kraft (P)

Department of Epidemiology Harvard TH Chan School of Public Health, Boston, MA, USA.
Program in Genetic Epidemiology and Statistical Genetics Harvard TH Chan School of Public Health Boston, Boston, MA, USA.

Allison W Kurian (AW)

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.

Yael Laitman (Y)

The Susanne Levy Gertner Oncogenetics Unit Chaim Sheba Medical Center, Ramat Gan, Israel.

Diether Lambrechts (D)

VIB Center for Cancer Biology, Leuven, Belgium.
Laboratory for Translational Genetics, Department of Human Genetics University of Leuven, Leuven, Belgium.

Loic Le Marchand (L)

Epidemiology Program University of Hawaii Cancer Center, Honolulu, HI, USA.

Jenny Lester (J)

Faculty of Medicine University of Heidelberg, Heidelberg, Germany.
David Geffen School of Medicine, Department of Obstetrics and Gynecology University of California at Los Angeles, Los Angeles, CA, USA.

Fabienne Lesueur (F)

Genetic Epidemiology of Cancer team, Inserm, U900, Paris, France.
Institut Curie Paris, Paris, France.
Mines ParisTech Fontainebleau, Paris, France.
PSL University Paris, Paris, France.

Tricia Lindstrom (T)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Adria Lopez-Fernández (A)

High Risk and Cancer Prevention Group Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Jennifer T Loud (JT)

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics National Cancer Institute, Bethesda, MD, USA.

Craig Luccarini (C)

Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Arto Mannermaa (A)

Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH Johanniter Krankenhaus, Bonn, Germany.
Translational Cancer Research Area University of Eastern Finland, Kuopio, Finland.
Institute of Clinical Medicine, Pathology and Forensic Medicine University of Eastern Finland, Kuopio, Finland.

Siranoush Manoukian (S)

Unit of Medical Genetics, Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Sara Margolin (S)

Department of Oncology, Södersjukhuset, Stockholm, Sweden.
Department of Clinical Science and Education, Södersjukhuset Karolinska Institutet, Stockholm, Sweden.

John W M Martens (JWM)

Department of Medical Oncology, Family Cancer Clinic Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Noura Mebirouk (N)

Genetic Epidemiology of Cancer team, Inserm, U900, Paris, France.
Institut Curie Paris, Paris, France.
Mines ParisTech Fontainebleau, Paris, France.
PSL University Paris, Paris, France.

Alfons Meindl (A)

Department of Gynecology and Obstetrics University of Munich, Campus Grosshadern, Munich, Germany.

Austin Miller (A)

NRG Oncology, Statistics and Data Management Center Roswell Park Cancer Institute, Buffalo, NY, USA.

Roger L Milne (RL)

Cancer Epidemiology Division Cancer Council Victoria, Melbourne, VIC, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health Monash University, Clayton, VIC, Australia.

Marco Montagna (M)

Immunology and Molecular Oncology, Unit Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Katherine L Nathanson (KL)

Basser Center for BRCA, Abramson Cancer Center University of Pennsylvania, Philadelphia, PA, USA.

Susan L Neuhausen (SL)

Department of Population Sciences Beckman Research Institute of City of Hope, Duarte, CA, USA.

Heli Nevanlinna (H)

Department of Genetics and Fundamental Medicine Bashkir State Medical University, Ufa, Russia.

Finn C Nielsen (FC)

Center for Genomic Medicine Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Katie M O'Brien (KM)

Epidemiology Branch National Institute of Environmental Health Sciences, NIH Research Triangle Park, Durham, NC, USA.

Olufunmilayo I Olopade (OI)

Center for Clinical Cancer Genetics The University of Chicago, Chicago, IL, USA.

Janet E Olson (JE)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Håkan Olsson (H)

Department of Cancer Epidemiology, Clinical Sciences Lund University, Lund, 22242, Sweden.

Ana Osorio (A)

Human Cancer Genetics Programme Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.

Laura Ottini (L)

Department of Molecular Medicine University La Sapienza, Rome, Italy.

Tjoung-Won Park-Simon (TW)

Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.

Michael T Parsons (MT)

Department of Genetics and Computational Biology QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Inge Sokilde Pedersen (IS)

Molecular Diagnostics Aalborg University Hospital, Aalborg, Denmark.
Clinical Cancer Research Center Aalborg University Hospital, Aalborg, Denmark.
Department of Clinical Medicine Aalborg University, Aalborg, Denmark.

Beth Peshkin (B)

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Paolo Peterlongo (P)

Genome Diagnostics Program IFOM - the FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy.

Julian Peto (J)

Department of Non-Communicable Disease Epidemiology London School of Hygiene and Tropical Medicine, London, UK.

Paul D P Pharoah (PDP)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Kelly-Anne Phillips (KA)

Department of Genetics and Computational Biology QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology The University of Melbourne, Melbourne, VIC, Australia.

Eric C Polley (EC)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Bruce Poppe (B)

Centre for Medical Genetics Ghent University, Gent, Belgium.

Nadege Presneau (N)

School of Life Sciences University of Westminster, London, UK.

Miquel Angel Pujana (MA)

Translational Research Laboratory IDIBELL (Bellvitge Biomedical Research Institute), Catalan Institute of Oncology, CIBERONC, Barcelona, Spain.

Kevin Punie (K)

Leuven Multidisciplinary Breast Center, Department of Oncology Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.

Paolo Radice (P)

Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.

Johanna Rantala (J)

Clinical Genetics Karolinska Institutet, Stockholm, Sweden.

Muhammad U Rashid (MU)

Molecular Genetics of Breast Cancer German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Basic Sciences Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan.

Gad Rennert (G)

Clalit National Cancer Control Center Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.

Hedy S Rennert (HS)

Clalit National Cancer Control Center Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.

Mark Robson (M)

Clinical Genetics Service, Department of Medicine Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Atocha Romero (A)

Medical Oncology Department Hospital Universitario Puerta de Hierro, Madrid, Spain.

Maria Rossing (M)

Center for Genomic Medicine Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Emmanouil Saloustros (E)

Department of Oncology University Hospital of Larissa, Larissa, Greece.

Dale P Sandler (DP)

Epidemiology Branch National Institute of Environmental Health Sciences, NIH Research Triangle Park, Durham, NC, USA.

Regina Santella (R)

Department of Epidemiology, Mailman School of Public Health Columbia University, New York, NY, USA.

Maren T Scheuner (MT)

Cancer Genetics and Prevention Program University of California San Francisco, San Francisco, CA, USA.

Marjanka K Schmidt (MK)

Womenís Cancer Program at the Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Psychosocial Research and Epidemiology The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.

Gunnar Schmidt (G)

Institute of Human Genetics Hannover Medical School, Hannover, Germany.

Christopher Scott (C)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Priyanka Sharma (P)

Department of Internal Medicine, Division of Medical Oncology University of Kansas Medical Center, Westwood, KS, USA.

Penny Soucy (P)

Genomics Center, Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Québec City, QC, Canada.

Melissa C Southey (MC)

Precision Medicine, School of Clinical Sciences at Monash Health Monash University, Clayton, VIC, Australia.
Department of Clinical Pathology The University of Melbourne, Melbourne, VIC, Australia.

John J Spinelli (JJ)

Population Oncology BC Cancer, Vancouver, BC, Canada.
School of Population and Public Health University of British Columbia, Vancouver, BC, Canada.

Zoe Steinsnyder (Z)

Clinical Genetics Research Lab, Department of Cancer Biology and Genetics Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Jennifer Stone (J)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
The Curtin UWA Centre for Genetic Origins of Health and Disease Curtin University and University of Western Australia, Perth, Western Australia, Australia.

Dominique Stoppa-Lyonnet (D)

Service de Génétique Institut Curie, Paris, France.
Department of Tumour Biology INSERM U830, Paris, France.
Université Paris Descartes, Paris, France.

Anthony Swerdlow (A)

Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
Division of Breast Cancer Research Institute of Cancer Research, London, UK.

Rulla M Tamimi (RM)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Epidemiology Harvard TH Chan School of Public Health, Boston, MA, USA.
Program in Genetic Epidemiology and Statistical Genetics Harvard TH Chan School of Public Health Boston, Boston, MA, USA.

William J Tapper (WJ)

Faculty of Medicine University of Southampton, Southampton, UK.

Jack A Taylor (JA)

Epidemiology Branch National Institute of Environmental Health Sciences, NIH Research Triangle Park, Durham, NC, USA.
Epigenetic and Stem Cell Biology Laboratory National Institute of Environmental Health Sciences, NIH Research Triangle Park, Triangle Park, NC, USA.

Mary Beth Terry (MB)

Department of Epidemiology, Mailman School of Public Health Columbia University, New York, NY, USA.

Alex Teulé (A)

Hereditary Cancer Program ONCOBELL-IDIBELL-IDIBGI-IGTP, Catalan Institute of Oncology, CIBERONC, Barcelona, Spain.

Darcy L Thull (DL)

Department of Medicine Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Marc Tischkowitz (M)

Program in Cancer Genetics, Departments of Human Genetics and Oncology McGill University, Montréal, QC, Canada.
Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Center, University of Cambridge, Cambridge, UK.

Amanda E Toland (AE)

Department of Cancer Biology and Genetics The Ohio State University, Columbus, OH, USA.

Diana Torres (D)

Molecular Genetics of Breast Cancer German Cancer Research Center (DKFZ), Heidelberg, Germany.
Institute of Human Genetics Pontificia Universidad Javeriana, Bogota, Colombia.

Alison H Trainer (AH)

Parkville Familial Cancer Centre Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
Department of medicine University Of Melbourne, Melbourne, VIC, Australia.

Thérèse Truong (T)

Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP) INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, France.

Nadine Tung (N)

Department of Medical Oncology Beth Israel Deaconess Medical Center, Boston, MA, USA.

Celine M Vachon (CM)

Department of Health Science Research, Division of Epidemiology Mayo Clinic, Rochester, MN, USA.

Ana Vega (A)

Fundación Pública Galega Medicina Xenómica-SERGAS, Instituto de Investigación Sanitaria Santiago de Compostela (IDIS); CIBERER, Santiago de Compostela, Spain.

Joseph Vijai (J)

Clinical Genetics Service, Department of Medicine Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Clinical Genetics Research Lab, Department of Cancer Biology and Genetics Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Qin Wang (Q)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Barbara Wappenschmidt (B)

Center for Hereditary Breast and Ovarian Cancer Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Center for Integrated Oncology (CIO) Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Clarice R Weinberg (CR)

Biostatistics and Computational Biology Branch National Institute of Environmental Health Sciences, NIH Research Triangle Park, Triangle Park, NC, USA.

Jeffrey N Weitzel (JN)

Clinical Cancer Genomics City of Hope, Duarte, CA, USA.

Camilla Wendt (C)

Department of Clinical Science and Education, Södersjukhuset Karolinska Institutet, Stockholm, Sweden.

Alicja Wolk (A)

Institute of Environmental Medicine Karolinska Institutet, Stockholm, Sweden.
Department of Surgical Sciences Uppsala University, Uppsala, Sweden.

Siddhartha Yadav (S)

Department of Oncology Mayo Clinic, Rochester, MN, USA.

Xiaohong R Yang (XR)

Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.

Drakoulis Yannoukakos (D)

Molecular Diagnostics Laboratory, INRASTES National Centre for Scientific Research íDemokritosí, Athens, Greece.

Wei Zheng (W)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center Vanderbilt University School of Medicine, Nashville, TN, USA.

Argyrios Ziogas (A)

Department of Epidemiology, Genetic Epidemiology Research Institute University of California Irvine, Irvine, CA, USA.

Kristin K Zorn (KK)

Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Sue K Park (SK)

Department of Preventive Medicine Seoul National University College of Medicine, Seoul, Korea.
Department of Biomedical Sciences Seoul National University Graduate School, Seoul, Korea.
Cancer Research Institute Seoul National University, Seoul, Korea.

Mads Thomassen (M)

Department of Clinical Genetics Odense University Hospital, Odence C, Denmark.

Kenneth Offit (K)

Clinical Genetics Service, Department of Medicine Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Clinical Genetics Research Lab, Department of Cancer Biology and Genetics Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Rita K Schmutzler (RK)

Center for Hereditary Breast and Ovarian Cancer Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Center for Integrated Oncology (CIO) Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Fergus J Couch (FJ)

Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, MN, USA.

Jacques Simard (J)

Department of Epidemiology, Genetic Epidemiology Research Institute University of California Irvine, Irvine, CA, USA.

Georgia Chenevix-Trench (G)

Department of Genetics and Computational Biology QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Centre for Cancer Genetic Epidemiology, Department of Oncology University of Cambridge, Cambridge, UK.

Nadine Andrieu (N)

Genetic Epidemiology of Cancer team, Inserm, U900, Paris, France. nadine.andrieu@curie.fr.
Institut Curie Paris, Paris, France. nadine.andrieu@curie.fr.
Mines ParisTech Fontainebleau, Paris, France. nadine.andrieu@curie.fr.
PSL University Paris, Paris, France. nadine.andrieu@curie.fr.

Antonis C Antoniou (AC)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. aca20@medschl.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH